JO
KLRS

John Overdeck’s Kalaris Therapeutics KLRS Stock Holding History

John Overdeck’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$97.1K Sell
23,847
-6,803
-22% -$35.3K ﹤0.01% 4892
2026
Q1 		$177K Buy
30,650
+2,891
+10% +$25.7K ﹤0.01% 4301
2025
Q4 		$234K Buy
+27,759
New +$177K ﹤0.01% 3698
2025
Q1 		– Sell
-11,591
Closed -$112K – 3572
2024
Q4 		$112K Sell
11,591
-1,242
-10% -$18.8K ﹤0.01% 2954
2024
Q3 		$239K Sell
12,833
-2,470
-16% -$43.2K ﹤0.01% 2754
2024
Q2 		$255K Buy
15,303
+1,484
+11% +$26.2K ﹤0.01% 2654
2024
Q1 		$240K Buy
13,819
+2,317
+20% +$37.8K ﹤0.01% 2646
2023
Q4 		$180K Buy
11,502
+10,005
+668% +$395K ﹤0.01% 2859
2023
Q3 		$74K Buy
+1,497
New +$102K ﹤0.01% 2776
2022
Q3 		– Sell
-3,393
Closed -$304K – 2899
2022
Q2 		$304K Sell
3,393
-1,643
-33% -$172K ﹤0.01% 2023
2022
Q1 		$782K Buy
5,036
+1,190
+31% +$237K ﹤0.01% 1812
2021
Q4 		$1.15M Buy
3,846
+2,411
+168% +$1.12M ﹤0.01% 2417
2021
Q3 		$827K Sell
1,435
-244
-15% -$113K ﹤0.01% 2792
2021
Q2 		$762K Buy
1,679
+122
+8% +$63K ﹤0.01% 2729
2021
Q1 		$838K Buy
+1,557
New +$1.31M ﹤0.01% 2477

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

John Overdeck's KLRS Position: Q2 2026 in Review

John Overdeck reduced its Kalaris Therapeutics (KLRS) stake by 22% in Q2 2026, selling an estimated $35.3K and leaving 23,847 shares worth $97.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4892.

John Overdeck first reported a position in KLRS in Q1 2021 and has held it in 15 quarters since. The position peaked at $1.15M in Q4 2021. 57 funds tracked by Wall St. Rank hold KLRS as of Q2 2026.

  • John Overdeck held 23,847 shares of Kalaris Therapeutics worth $97.1K as of Q2 2026.
  • John Overdeck sold 6,803 Kalaris Therapeutics shares in Q2 2026, an estimated $35.3K.
  • Kalaris Therapeutics made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #4892 holding.
  • John Overdeck first reported a position in Kalaris Therapeutics in Q1 2021 and has held it in 15 quarters since.
  • John Overdeck's Kalaris Therapeutics position peaked at $1.15M in Q4 2021.
  • 57 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.